Skip to content
Litigation opposing drug price controls in the Inflation Reduction Act (IRA) has yet to have a major impact, but the cases are still ongoing […]
BIO 2025: Legal experts break down cases against IRA price controls Read More »
Given the essential role that intellectual property plays in the development of lifesaving scientific advances, we need to defend and strengthen policy that protects
Protect IP protections, BIO 2025 panel urges Read More »
Patents enable the innovation that produces new lifesaving treatments while ensuring a competitive market, the top IP expert for the Biotechnology Innovation Organization (BIO)
BIO expert explains patents at DOJ and FTC listening session Read More »
The exciting new developments we’re seeing in biotechnology must be supported by equally innovative policy, according to Fritz Bittenbender, the new Chair of the
A conversation with Fritz Bittenbender, new BIO Board Chair Read More »
Even if they aren’t making revenue, small biotechs can face onerous reporting requirements that cost $1 million or more, cutting into the firms’ ability
Onerous reporting requirements crushing small biotechs, BIO Board member testifies Read More »
We often talk about the exciting jumps in technology and innovation that improve and save lives. What is less frequently discussed is how regulation
BIO 2025: The innovation race vs. the regulatory pace Read More »
Established in 2012, the Pediatric Priority Review (PPRV) program offers a powerful incentive for companies to develop treatments for rare conditions affecting children. Even
BIO 2025: What is the PRV program and why does it matter? Read More »
The threat to America’s leadership in biotech is a threat to our national security that we need to address now, two members of a
Biotech and national security: ‘Time to act but no time to wait’ Read More »
Food and Drug Administration (FDA) Commissioner Martin A. Makary, M.D., M.P.H., sat down with the Biotechnology Innovation Organization (BIO) President and CEO John F.
BIO 2025: Commissioner Martin Makary, M.D., M.P.H., discusses vision for FDA Read More »
Biotech’s contribution to America’s biodefense can only be supported through public-private partnerships, but the public sector must provide adequate support and private actors need
BIO 2025: A strong biodefense requires government-industry partnerships Read More »
